

Title (en)  
PHARMACEUTICAL COMPOSITION FOR TREATING DYSGLYCEMIA AND GLUCOSE EXCURSIONS

Title (de)  
Pharmazeutische Zusammensetzung zur Behandlung von Dysglykämie und Glukose-Exkursionen

Title (fr)  
COMPOSITION PHARMACEUTIQUE POUR LE TRAITEMENT DE LA DYSGLYCÉMIE ET DES OSCILLATIONS DE LA GLYCÉMIE

Publication  
**EP 2231128 B1 20181226 (EN)**

Application  
**EP 09809138 A 20090824**

Priority  
• CA 2009001166 W 20090824  
• CA 2638240 A 20080829

Abstract (en)  
[origin: CA2638240C] The present application relates to pharmaceutical compositions for reducing glucose excursions in a normal subject or a subject having an insulin-related disorder or dysglycemia. The pharmaceutical composition contains one or more active agent-containing layers, which each contain a dry blended mixture including a therapeutically effective amount of a polar ionizable insulin-sensitizing oral hypoglycemic agent or a pharmaceutically acceptable salt thereof, and an amphipathic compound in monomeric form consisting of an amphipathic ionic compound in monomeric form. Each dry blended mixture contains a sufficient amount of the amphipathic ionic compound such that upon contact with an aqueous fluid, the amphipathic ionic compound forms a reverse micelle comprising the polar ionizable insulin-sensitizing oral hypoglycemic agent. The present invention also relates to a use of a modified release pharmaceutical composition comprising a therapeutically effective amount of an insulin-sensitizing oral hypoglycemic agent for sensitizing pre-prandial (basal) insulin levels and/or reducing postprandial glucose excursions in a normal patient or a patient having an insulin-related disorder.

IPC 8 full level  
**A61K 9/24** (2006.01); **A61K 31/155** (2006.01); **A61P 3/10** (2006.01)

CPC (source: EP US)  
**A61K 9/2013** (2013.01 - EP US); **A61K 9/2027** (2013.01 - EP US); **A61K 9/2054** (2013.01 - EP US); **A61K 9/2086** (2013.01 - EP US); **A61K 31/155** (2013.01 - EP US); **A61K 45/06** (2013.01 - EP US); **A61P 3/08** (2017.12 - EP); **A61P 3/10** (2017.12 - EP); **A61P 5/48** (2017.12 - EP); **A61P 5/50** (2017.12 - EP)

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DOCDB simple family (publication)  
**CA 2638240 A1 20081118; CA 2638240 C 20100202**; AU 2009287368 A1 20100304; AU 2009287368 A2 20100624; AU 2016228159 A1 20161006; AU 2016228159 B2 20180412; BR PI0917922 A2 20160726; CN 101909604 A 20101208; CN 101909604 B 20130814; EP 2231128 A1 20100929; EP 2231128 A4 20131127; EP 2231128 B1 20181226; ES 2708498 T3 20190409; HR P20190178 T1 20190503; JP 2012500810 A 20120112; JP 2014159470 A 20140904; JP 5902228 B2 20160413; MX 2011002227 A 20110729; MX 337175 B 20160215; TR 201901238 T4 20190221; US 2011159045 A1 20110630; US 9061061 B2 20150623; WO 2010022497 A1 20100304

DOCDB simple family (application)  
**CA 2638240 A 20080829**; AU 2009287368 A 20090824; AU 2016228159 A 20160912; BR PI0917922 A 20090824; CA 2009001166 W 20090824; CN 200980102157 A 20090824; EP 09809138 A 20090824; ES 09809138 T 20090824; HR P20190178 T 20190128; JP 2011524144 A 20090824; JP 2014098181 A 20140509; MX 2011002227 A 20090824; TR 201901238 T 20090824; US 74430109 A 20090824